TWI315197B - Combinations - Google Patents

Combinations

Info

Publication number: TWI315197B
Authority: TW; Taiwan
Prior art keywords: combinations
Prior art date: 2000-08-22

Application number

TW090120391A

Other languages

English (en)

Inventor

Allison Malcolm

Regan Gatlin Marjorie

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2001-08-20

Publication date

2009-10-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24581689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI315197(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-08-20 Application filed by Novartis Ag filed Critical Novartis Ag

2009-10-01 Application granted granted Critical

2009-10-01 Publication of TWI315197B publication Critical patent/TWI315197B/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW090120391A 2000-08-22 2001-08-20 Combinations TWI315197B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US64364100A	2000-08-22	2000-08-22

Publications (1)

Publication Number	Publication Date
TWI315197B true TWI315197B (en)	2009-10-01

Family

ID=24581689

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
TW097122772A TWI327469B (en)	2000-08-22	2001-08-20	Pharmaceutical composition
TW090120391A TWI315197B (en)	2000-08-22	2001-08-20	Combinations
TW097122770A TWI327468B (en)	2000-08-22	2001-08-20	Pharmaceutical composition

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
TW097122772A TWI327469B (en)	2000-08-22	2001-08-20	Pharmaceutical composition

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW097122770A TWI327468B (en)	2000-08-22	2001-08-20	Pharmaceutical composition

Country Status (15)

Country	Link
US (1)	US20040034065A1 (zh)
EP (3)	EP2138175A3 (zh)
JP (4)	JP2004514654A (zh)
AR (1)	AR033390A1 (zh)
AT (1)	ATE399010T1 (zh)
AU (1)	AU2001287698A1 (zh)
CL (1)	CL2009001899A1 (zh)
CY (1)	CY1111698T1 (zh)
DE (1)	DE60134575D1 (zh)
DK (1)	DK1351683T3 (zh)
MY (1)	MY141012A (zh)
PE (1)	PE20020617A1 (zh)
PT (1)	PT1351683E (zh)
TW (3)	TWI327469B (zh)
WO (1)	WO2002015933A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
TW200304813A (en) *	2002-03-11	2003-10-16	Novartis Ag	Salts of organic acid
AU2002356419A1 (en)	2002-06-17	2003-12-31	Themis Laboratories Private Limited	Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US7232828B2 (en) *	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
CN100438911C (zh) *	2002-12-27	2008-12-03	武田药品工业株式会社	体重增加抑制剂
ES2535291T3 (es) *	2003-04-15	2015-05-08	Daiichi Sankyo Company, Limited	Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas
EP1631556A1 (en) *	2003-05-16	2006-03-08	Novartis AG	Pharmaceutical composition comprising valsartan
WO2005092319A1 (en) *	2004-03-29	2005-10-06	Ranbaxy Laboratories Limited	Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
AU2005243214B2 (en)	2004-04-29	2011-07-07	U.S. Smokeless Tobacco Company Llc	Nicotiana nucleic acid molecules and uses thereof
JP4914714B2 (ja) *	2004-05-11	2012-04-11	キッセイ薬品工業株式会社	脂質代謝異常の予防または治療用医薬組成物
WO2005117591A2 (en) *	2004-05-28	2005-12-15	Andrx Labs Llc	Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
JP2008515767A (ja) *	2004-10-07	2008-05-15	武田薬品工業株式会社	代謝症候群予防治療剤
JP2007099764A (ja) *	2005-09-09	2007-04-19	Ajinomoto Co Inc	血糖低下剤
WO2010122927A1 (ja) *	2009-04-20	2010-10-28	第一三共株式会社	糖尿病由来神経再生遅延の予防又は治療のための医薬
JP6854384B2 (ja) *	2017-07-17	2021-04-07	イーライリリーアンドカンパニー	医薬組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2951135A1 (de)	1979-12-19	1981-06-25	Hoechst Ag, 6230 Frankfurt	Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS6354321A (ja)	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
CA1334092C (en)	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
DE69033469T2 (de)	1989-06-14	2000-09-07	Smithkline Beecham Corp., Philadelphia	Imidazoalkensäure
JP3262329B2 (ja)	1990-01-24	2002-03-04	アイ．バックレイ，ダグラス	糖尿病治療に有用なｇｌｐ―１アナログ
PH30484A (en)	1990-02-19	1997-05-28	Ciba Geigy	Acy compounds pharmaceutical composition containing said compound and method of use thereof
IE910913A1 (en)	1990-03-20	1991-09-25	Sanofi Sa	N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) *	1990-05-15	1994-03-29	E. R. Squibb & Sons, Inc.	Method for preventing onset of hypertension employing a cholesterol lowering drug
SI9210098B (sl)	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5616599A (en)	1991-02-21	1997-04-01	Sankyo Company, Limited	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
AU654331B2 (en)	1991-03-30	1994-11-03	Kissei Pharmaceutical Co. Ltd.	Succinic acid compounds
PL170210B1 (pl)	1991-06-21	1996-11-29	Thomae Gmbh Dr K	Sposób wytwarzania nowego kwasu (S)(+)-2-etoksy-4-/N-/1-(2-piperydynofenylo)-3-metylo- 1-butyloaminokarbonylometylo/-benzoesowego i jego soli PL
ATE149483T1 (de)	1991-07-30	1997-03-15	Ajinomoto Kk	Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
TW226375B (zh)	1991-10-24	1994-07-11	American Home Prod
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
WO1995024901A1 (en) *	1994-03-17	1995-09-21	Ciba-Geigy Ag	Treatment of diabetic nephropathy with valsartan
CA2186606A1 (en) *	1994-03-29	1995-10-05	Edward B. Nelson	Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
US5488510A (en)	1994-07-26	1996-01-30	Lemay; Edward J.	Enhanced depth perception viewing device for television
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
SK283348B6 (sk) *	1996-04-05	2003-06-03	Takeda Chemical Industries, Ltd.	Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
JPH11315034A (ja) *	1998-03-04	1999-11-16	Takeda Chem Ind Ltd	アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
FR2778103A1 (fr) *	1998-04-29	1999-11-05	Sanofi Sa	Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
AU766831B2 (en) *	1998-05-11	2003-10-23	Takeda Pharmaceutical Company Limited	Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
PT2322174E (pt) *	1998-07-10	2015-10-27	Novartis Pharma Gmbh	Utilização combinada de valsartan e bloqueadores do canal de cálcio com objetivos terapêuticos
CO5150173A1 (es) *	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB0001662D0 (en) *	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
NZ517468A (en) *	1999-08-30	2004-02-27	Aventis Pharma Gmbh	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
TWI302149B (en) *	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
WO2001082916A2 (en) *	2000-05-03	2001-11-08	Tularik Inc.	Combination therapeutic compositions and methods of use
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20020037829A1 (en) *	2000-08-23	2002-03-28	Aronson Peter S.	Use of DPPIV inhibitors as diuretic and anti-hypertensive agents

2001
- 2001-08-17 PE PE2001000825A patent/PE20020617A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103950A patent/AR033390A1/es not_active Application Discontinuation
- 2001-08-20 AT AT01967289T patent/ATE399010T1/de active
- 2001-08-20 TW TW097122772A patent/TWI327469B/zh not_active IP Right Cessation
- 2001-08-20 EP EP09171372A patent/EP2138175A3/en not_active Withdrawn
- 2001-08-20 EP EP08154993A patent/EP1980249A3/en not_active Withdrawn
- 2001-08-20 JP JP2002520854A patent/JP2004514654A/ja not_active Withdrawn
- 2001-08-20 DK DK01967289T patent/DK1351683T3/da active
- 2001-08-20 TW TW090120391A patent/TWI315197B/zh not_active IP Right Cessation
- 2001-08-20 US US10/362,340 patent/US20040034065A1/en not_active Abandoned
- 2001-08-20 WO PCT/EP2001/009587 patent/WO2002015933A2/en not_active Ceased
- 2001-08-20 AU AU2001287698A patent/AU2001287698A1/en not_active Abandoned
- 2001-08-20 PT PT01967289T patent/PT1351683E/pt unknown
- 2001-08-20 EP EP01967289A patent/EP1351683B1/en not_active Expired - Lifetime
- 2001-08-20 DE DE60134575T patent/DE60134575D1/de not_active Expired - Lifetime
- 2001-08-20 TW TW097122770A patent/TWI327468B/zh not_active IP Right Cessation
- 2001-08-21 MY MYPI20013925A patent/MY141012A/en unknown
2008
- 2008-09-24 CY CY20081101043T patent/CY1111698T1/el unknown
2009
- 2009-09-24 CL CL2009001899A patent/CL2009001899A1/es unknown
- 2009-09-29 JP JP2009224224A patent/JP2010043101A/ja not_active Withdrawn
2012
- 2012-10-17 JP JP2012230073A patent/JP2013049683A/ja not_active Withdrawn
2015
- 2015-07-02 JP JP2015133314A patent/JP2015205909A/ja active Pending

Also Published As

Publication number	Publication date
EP1980249A3 (en)	2010-04-28
EP1351683B1 (en)	2008-06-25
MY141012A (en)	2010-02-25
EP2138175A3 (en)	2010-01-13
EP2138175A2 (en)	2009-12-30
EP1980249A2 (en)	2008-10-15
CY1111698T1 (el)	2015-10-07
TWI327468B (en)	2010-07-21
TW200843741A (en)	2008-11-16
PT1351683E (pt)	2008-09-18
AR033390A1 (es)	2003-12-17
PE20020617A1 (es)	2002-08-05
JP2015205909A (ja)	2015-11-19
AU2001287698A1 (en)	2002-03-04
TWI327469B (en)	2010-07-21
TW200838503A (en)	2008-10-01
EP1351683A2 (en)	2003-10-15
CL2009001899A1 (es)	2010-02-12
JP2013049683A (ja)	2013-03-14
JP2004514654A (ja)	2004-05-20
WO2002015933A2 (en)	2002-02-28
DK1351683T3 (da)	2008-10-20
WO2002015933A3 (en)	2003-08-14
JP2010043101A (ja)	2010-02-25
DE60134575D1 (de)	2008-08-07
US20040034065A1 (en)	2004-02-19
ATE399010T1 (de)	2008-07-15

Publication	Publication Date	Title
DE60138955D1 (en)	2009-07-23	Xanthin-phosphodiesteras-v-inhibitoren
DE50112740D1 (en)	2007-08-30	Strangführungselement
GB0021578D0 (en)	2000-10-18	Flaves
TWI315197B (en)	2009-10-01	Combinations
DE50112014D1 (en)	2007-03-22	Stiftheizer
DE50008626D1 (en)	2004-12-16	Substituierte aminomethyl-phenyl-cyclohexanderivate
AU6619001A (en)	2002-01-08	Liquid-pourers
GB0012117D0 (en)	2000-07-12	Aquwoua mulripolymwe siapweaiona
AU4831301A (en)	2001-08-27	Gm-negative ehv-mutants
GB0017353D0 (en)	2000-08-30	Hitch-a-lone
GB0010887D0 (en)	2000-06-28	Piano-guitar
GB0010038D0 (en)	2000-06-14	Securette
GB0018085D0 (en)	2000-09-13	Trolleybox
GB0015600D0 (en)	2000-08-16	Case-holders
AU2117P (en)	2002-10-02	Gauka Gaura lindheimeri
GB0009547D0 (en)	2000-06-07	Grass-chopper
GB0021894D0 (en)	2000-10-25	Polupeptide
GB0006136D0 (en)	2000-05-03	Bulustrade
GB0006729D0 (en)	2000-05-10	Netlocker
GB0008345D0 (en)	2000-05-24	Milk-maid
GB0021249D0 (en)	2000-10-18	Guardmine
GB0013736D0 (en)	2000-07-26	Lift-n-feed
GB0009546D0 (en)	2000-06-07	Wheeley
GB0009534D0 (en)	2000-06-07	Escapeapparatus
GB0005329D0 (en)	2000-04-26	Worrawee innagen

Legal Events

Date	Code	Title	Description
2017-07-01	MM4A	Annulment or lapse of patent due to non-payment of fees